Finasteride generics bioequivalence to propecia ema fda bfarm?

Short answer: Yes. In major markets (FDA in the US, EMA/BfArM in the EU, including Germany), generic finasteride products must be bioequivalent to Propecia (the reference product) to be approved.

What that means in practice
- Bioequivalence (BE) means the generic should have no meaningful difference in rate and extent of absorption compared with Propecia.
- The standard BE criteria are that the 90% confidence intervals for the ratio of the generic to the reference for key PK parameters (usually Cmax and AUC) fall within 80–125%. Some guidelines allow slightly different rules for highly variable products, but finasteride is not typically treated as highly variable.
- Generics achieve approval by conducting BE studies (usually single-dose PK studies in healthy volunteers under fasting or fed conditions, per the product’s guidelines).

How to verify BE status
- United States (FDA): Look up the product in the FDA Orange Book. An AB-rated entry indicates therapeutic equivalence to the reference brand (Propecia) and that it is considered interchangeable.
- European Union (EMA) / Germany (BfArM): BE is demonstrated per EU BE guidelines; check the product labeling and the EMA/BeRx databases. The EU uses AB-rated status to denote BE.
- In short, if a finasteride generic is approved as BE to Propecia, it should be therapeutically equivalent and interchangeable.

Notes
- Propecia is 1 mg finasteride (brand by the brand owner); generics cover the same 1 mg dosage. There are also 5 mg products (Proscar), which are separate approvals.
- Excipients can differ between generics, but that should not affect BE or clinical efficacy. If you have allergies or sensitivity to a particular excipient, mention it to your pharmacist or prescriber.
- If you want, tell me your country and I can point you to the exact BE status for a specific generic product (e.g., AB rating in the FDA Orange Book or EU/BE status in the EMA/BfArM databases).